Test Price
3,000 AED✅ Home Collection Available
Abnormal Mineralization Panel (Genetic Test) in UAE | 3000 AED | DHA Licensed
Executive Summary & Core Metrics
The Abnormal Mineralization Panel is a comprehensive Next-Generation Sequencing (NGS) assay designed to identify pathogenic variants in 58 critical genes associated with complex skeletal, dermatological, and immunological mineralization disorders. Performed at DNA Labs UAE, an ISO 9001:2015 certified facility under DHA License 1143, this test provides clinicians with a definitive etiological diagnosis to guide personalized therapeutic strategies.
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Sequencing & Bioinformatics Pipeline.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Complimentary Telephonic Post-Test Genetic Counseling & Result Interpretation by our Consultant Medical Genetics team.
Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
This advanced molecular diagnostic test analyzes the complete coding regions of 58 carefully selected genes central to calcium-phosphate homeostasis and extracellular matrix integrity. By leveraging Next-Generation Sequencing (NGS) coupled with a clinical-grade bioinformatics pipeline, the panel definitively identifies single nucleotide variants, indels, and copy number variations (CNVs) in genes such as ABCC6, ALPL, and COL1A1/2. This molecular precision supersedes the limitations of traditional biochemical screening, offering clinicians a clear genomic roadmap for patient management.
| Feature | Our Test (ISO Certified NGS) | Standard Biochemical Panel |
|---|---|---|
| Precision & Depth | Molecular resolution identifying SNVs, indels, and CNVs in 58 target genes. | Phenomenological measurement of calcium/phosphate; fluctuates with diet and hormones. |
| Methodology | Next Generation Sequencing (NGS) with Clinical-Grade Bioinformatics Pipeline. | Automated Colorimetric / Photometric Assay. |
| Turnaround Time | 3 to 4 Weeks (Comprehensive Clinical Reporting). | 1 to 2 Days (Non-specific screening result). |
Physician Insight & Safety Protocols
"In my practice, I initiate this comprehensive NGS panel when a patient presents with a perplexing mix of symptoms—like recurrent pathological fractures paired with unexplained ectopic calcifications—that elude standard diagnostic pathways. It is vital to understand that while this test excels in identifying the root genetic cause, the results must be meticulously correlated with the patient's full phenotype and detailed family history. Patients must not discontinue or adjust any prescribed medications, such as bisphosphonates or calcilytics, without direct consultation with their managing physician."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory: Safe Testing & Medication Protocol
- Medication Warning: Do not discontinue any prescribed therapy without consulting your doctor. This test identifies genetic etiology and does not measure current response to treatment.
- Minors Compliance: Testing of individuals under 18 years strictly requires the explicit consent of a legal guardian and a documented pre-test genetic counseling session, in full compliance with UAE Federal Law.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria (Home Collection): Patients who are hemodynamically unstable, have a known history of severe vasovagal syncope during venipuncture, or are in acute metabolic crisis require specimen collection strictly within a monitored hospital facility. Mobile phlebotomy is disabled for these cases for patient safety.
- Emergency Red Flags: If you experience sudden, severe bone pain, acute loss of neurological function, or tetany, proceed immediately to the nearest Emergency Department. This genetic test is a diagnostic tool, not an emergency intervention.
Patient FAQ & Clinical Guidance
1. How does this NGS genetic panel definitively diagnose abnormal mineralization disorders?
A definitive molecular diagnosis is achieved by identifying pathogenic variants within the 58 genes specifically governing calcium-phosphate homeostasis and extracellular matrix integrity. This provides a precise genetic etiology, moving beyond the non-specific results of traditional biochemical screens.
2. What are the mandatory pre-test steps for UAE regulatory compliance?
Mandatory pre-test compliance includes a comprehensive clinical history review and a dedicated genetic counseling session with a licensed professional to map your family pedigree. This is a regulatory requirement to ensure informed consent and accurate genomic interpretation.
3. What action is required if my result identifies a Variant of Uncertain Significance (VUS)?
A VUS finding does not constitute a positive or negative diagnosis. It necessitates a multi-disciplinary re-evaluation involving your referring specialist and geneticist to determine its clinical relevance and guide appropriate follow-up.
UAE Regulatory & Data Privacy Adherence
Your Data is Protected Under UAE Law
DNA Labs UAE strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is anonymized, encrypted, and processed exclusively within the UAE. Clinical safety and patient consent protocols align with Federal Decree-Law No. 4 of 2016 on Medical Liability. Our facility is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139), ensuring the highest standards of quality and data security.
Clinical & Logistical Metadata
| Test Name | Abnormal Mineralization Panel (Genetic Test) |
| Price (AED) | 3,000 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) |
| Methodology Used | Next-Generation Sequencing (NGS) with Clinical-Grade Bioinformatics Pipeline |
| ICD-10-CM Code | E83.39 (Disorder of phosphorus metabolism) |
| LOINC Code | 101363-0 (Genetic analysis of 58 genes associated with mineralization disorders) |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians